The Effects of Pumpkin Seed Oil Supplementation on Cardiovascular Function in Postmenopausal Women.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03716960|
Recruitment Status : Completed
First Posted : October 23, 2018
Last Update Posted : October 24, 2018
Postmenopausal women have a higher prevalence of cardiovascular (CV) disease than age-match men. Growing evidence from rat studies have demonstrated CV-protective effects of pumpkin seed oil (PSO).
The investigators hypothesis is that PSO would improve CV health in postmenopausal women.
|Condition or disease||Intervention/treatment||Phase|
|Elevated Blood Pressure Hypertension||Other: Pumpkin Seed Oil Other: Placebo||Not Applicable|
The purpose of the study is to examine the effects of 6 weeks of PSO on arterial and autonomic function in postmenopausal women. Specific aims of the study are to:
To investigate the extent to which PSO will improve cardiovascular disease risk factors by assessing arterial stiffness, aortic BP and wave reflection, and autonomic function (heart rate variability).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||23 participants|
|Intervention Model:||Parallel Assignment|
|Primary Purpose:||Basic Science|
|Official Title:||The Effects of Pumpkin Seed Oil Supplementation on Vascular Hemodynamics, Stiffness and Cardiac Autonomic Function in Postmenopausal Women.|
|Actual Study Start Date :||September 1, 2017|
|Actual Primary Completion Date :||June 30, 2018|
|Actual Study Completion Date :||June 30, 2018|
Experimental: Pumpkin Seed Oil
This arm involved 6 weeks of PSO consumption. Subject were supplemented with 3 g/day of PSO which was ingested in the form of 1g capsules with each main meal of the day (breakfast, lunch and dinner). Likewise,
Other: Pumpkin Seed Oil
This intervention consisted of 6 weeks of PSO consumption. Subject were supplemented with 3 g/day of PSO which was ingested in the form of 1g capsules with each main meal of the day (breakfast, lunch and dinner).
Placebo Comparator: Placebo
This arm involved 6 weeks of placebo consumption. Subject consumed 1 capsule of maltodextrin with each main meal of the day to match the dose and number of capsules ingested daily by the PSO group.
This intervention consisted of 6 weeks of placebo consumption. Subject consumed 1 capsule of maltodextrin with each main meal of the day to match the dose and number of capsules ingested daily by the PSO group.
- Blood pressure [ Time Frame: 6 weeks ]Non-invasive measures of brachial and aortic blood pressure
- Pressure Wave Reflection [ Time Frame: 6 weeks ]Using the augmentation index
- Arterial Stiffness [ Time Frame: 6 weeks ]Using the stiffness index
- Heart rate variability [ Time Frame: 6 weeks ]R-R intervals were collected during 6 min using a validated wireless monitor (Polar 800CX; Polar Electro OY, Kempele, Finland) via a chest strap interfaced with a PC. All R-R intervals were inspected for artifacts and premature beats.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03716960
|United States, Virginia|
|Arlington, Virginia, United States, 22207|
|Principal Investigator:||Alexei Wong, Ph.D||Marymount University|